drugset / Trial / NCT01750684
AC105 in Patients With Acute Traumatic Spinal Cord Injury
Phase 2
Terminated
15 enrolled
Acorda Therapeutics
DP Clinical, Inc. · collabUnited States Department of Defense · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The principal aim of this study was to establish the feasibility of rapid administration, safety, and tolerability of AC105 in patients with acute spinal cord injury.
Timeline
- Start
- 2013-07
- Primary completion
- 2015-02
- Completion
- 2015-05
Outcome
Outcome not reported
Stopped (Enrollment): “The study was terminated by the Sponsor due to insufficient enrollment.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | AC105 | Unknown | — | Intravenous |